Breast Cancer

The survival benefit derived from T-DM1—particularly invasive disease-free survival and overall survival—persisted throughout 8 years of follow-up in HER2-positive early breast cancer with residual invasive disease.

Overall, the transition from breast to genitourinary cancer has added depth and dimension to my knowledge of cancer care.

Findings presented at the 2023 San Antonio Breast Cancer Symposium described some possible avenues for artificial intelligence to be useful in breast cancer care.

The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.

Data from the phase 3 EMERALD trial showed that elacestrant’s benefit was consistent across various subgroups.

Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.

Trastuzumab deruxtecan showed the longest time to next treatment in patients with HER2-positive breast cancer or with stable HER2-low disease among the primary and metastatic setting.

The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.

Different subsets of patients with estrogen receptor-positive breast cancer achieved better pathologic complete response rates with neoadjuvant pembrolizumab/chemotherapy vs placebo/chemotherapy.

The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

Patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer reported positive outcomes following treatment with capivasertib plus fulvestrant.

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.

Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.

The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

Balancing quality-of-life concerns with treatment goals is complicated for young patients with hormone-sensitive breast cancers.

Patients with metastatic hormone receptor-positive breast cancer treated with datopotamab deruxtecan experienced a statistically significant and clinically meaningful improvement in progression-free survival.

Receiving a breast cancer diagnosis and undergoing treatment as a young adult takes a physical and emotional toll.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.

Reduced-dose or partial-breast radiotherapy showed comparable safety and efficacy outcomes compared with whole-breast radiotherapy.

Patients with early breast cancer may safely choose a shorter course of radiation therapy following reconstruction.

Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.

For patients with ER-positive breast cancer who remain premenopausal—or regain ovarian function—following chemotherapy, 2 years of ovarian suppression may be beneficial.

Ryan Tamargo, NP, AONCP, highlights how a new diagnostic tool can help improve accurate inflammatory breast cancer diagnoses.

Stronger interventions are needed to improve adjuvant treatment rates among breast cancer survivors.

White patients have the oldest average at diagnosis at 64.5 years, whereas Hispanic or Latino patients have the youngest average age at 57.2 years.

Subcutaneous trastuzumab demonstrated a safety profile that is consistent with the known profile with intravenous administration.

At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.